<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04569435</url>
  </required_header>
  <id_info>
    <org_study_id>ANX005-ALS-01</org_study_id>
    <nct_id>NCT04569435</nct_id>
  </id_info>
  <brief_title>Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annexon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Annexon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with&#xD;
      Amyotrophic Lateral Sclerosis ((ALS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase 2a, multi-center, open label, proof-of-biology study of ANX005 will be&#xD;
      administered to up to approximately 24 subjects with Amyotrophic Lateral Sclerosis (ALS) for&#xD;
      up to 12 weeks.&#xD;
&#xD;
      Induction Dose: Each subject will receive induction dosing of ANX005 on Days 1 and 5 or 6&#xD;
      (5/6).&#xD;
&#xD;
      Maintenance Dose: Each subject will receive a maintenance dose of ANX005 every 2 weeks (Weeks&#xD;
      2, 4, 6, 8, and 10). Maintenance doses are expected to be completed over approximately 4-5&#xD;
      hours.&#xD;
&#xD;
      Follow-up visits will be on Weeks 12, 16, and 24. All subjects will be contacted by phone 6&#xD;
      months after study completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>ANX005 administered for up to 12 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (Safety and Tolerability) of ANX005</measure>
    <time_frame>Up to week 12</time_frame>
    <description>As measured by incidence of TEAEs, SAEs, AEs related to ANX005, SAEs related to ANX005, Grade 3 or higher AEs, Grade 3 or higher AEs related to ANX005, AEs leading to study or treatment discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ANX005</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Concentrations of ANX005 in serum over time (up to Week 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ANX005</measure>
    <time_frame>Day 1 and Week 10</time_frame>
    <description>ANX005 Day 1 and Week 10 PK parameters (eg, Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of ANX005</measure>
    <time_frame>Day 1 and Week 10</time_frame>
    <description>ANX005 Day 1 and Week 10 PK parameters (eg, AUC0-t)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamics (PD) effects of ANX005</measure>
    <time_frame>up to Week 24</time_frame>
    <description>Change in free C1q concentrations in serum over time (up to Week 24)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ANX005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANX005</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>ANX005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of ALS according to the World Federation of Neurology revised E1 Escorial&#xD;
             criteria.&#xD;
&#xD;
          2. Onset of weakness within 3 years prior to enrollment.&#xD;
&#xD;
          3. Slow Vital Capacity ≥ 60% of predicted normal adjusted for sex, age, and height (from&#xD;
             the sitting position).&#xD;
&#xD;
          4. ALSFRS-R ≥ 30 at the Screening Visit.&#xD;
&#xD;
          5. If female, must be postmenopausal, surgically sterilized, or agree to use highly&#xD;
             effective methods of contraception from screening through Week 24.&#xD;
&#xD;
          6. Males with a woman partner of childbearing potential must agree to use highly&#xD;
             effective methods of contraception from Screening through Week 24.&#xD;
&#xD;
          7. Documented history of vaccinations within 5 years prior to screening visit against&#xD;
             encapsulated bacterial pathogens.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant, ongoing illness or medical condition that would jeopardize the&#xD;
             safety of the subject, limit participation, or compromise the interpretation of the&#xD;
             safety data derived from the subject.&#xD;
&#xD;
          2. Subjects with body weight &gt; 150 kg.&#xD;
&#xD;
          3. An ANA titer ≥ 1:160.&#xD;
&#xD;
          4. Clinically significant intercurrent illness, medical condition, or medical history&#xD;
             that would jeopardize the safety of the subject, limit participation, or compromise&#xD;
             the interpretation of the data derived from the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lahar Mehta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Annexon, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>650-822-5500</phone>
    <email>clinicaltrials@annexonbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Annexon Investigational Site 04</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 01</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>9492868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 05</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 02</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 03</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 06</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>650-822-5500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 10</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6508225500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 11</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>N8 E3B 0C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6508225500</phone>
      <email>Clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 09</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6508225500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 07</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6508225500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annexon Investigational Site 08</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6508225500</phone>
      <email>clinicaltrials@annexonbio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

